Fredrik Frejd, Chief Scientific Officer at Affibody, talked to Drug Discovery World about how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. 

The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024.  

This commercial validation has sparked intense interest from both pharmaceutical companies and investors, with multiple billion-dollar acquisitions in the radiopharmaceutical space signalling confidence in the therapeutic approach. 

Read the full story here.